CuraLife

Company Overview

Snapshot

Founded in November 2013 by Ron Elul, Ofer Yigdal, Alberto Iore, Tal Zimerman, and Haviv Almog, CuraLife operates with 11–50 employees. The company secured its initial seed funding in October 2021, with Catalyst participating. A significant milestone for CuraLife was the acquisition of GlucoMe in January 2021.

Business overview

CuraLife is a Health Tech & Life Sciences company focused on maximizing patient health outcomes through nutraceutical offerings and digital therapeutics. The company has developed a chronic disease management platform that provides therapeutic supplements, peer-to-peer support, behavior therapy, and virtual care. Its flagship product, CuraLin, is a natural glucose support supplement designed to help maintain healthy blood sugar levels, blending Ayurvedic practices with modern science. CuraLife's solutions, commercially launched in 2017, serve markets in over 50 countries, targeting individuals with chronic conditions like type-2 diabetes.

Strategic signal

In October 2021, CuraLife secured seed funding from Catalyst. This investment signals continued confidence in CuraLife's approach to chronic disease management through natural supplements and digital therapeutics, supporting its mission to expand its reach and impact in the global health tech market.

Company Intelligence Q&A

What is CuraLife's primary focus?

CuraLife focuses on maximizing patient health outcomes through nutraceutical offerings and digital therapeutics, particularly for chronic conditions like type-2 diabetes.

When did CuraLife commercially launch its solutions?

CuraLife commercially launched its solutions in 2017, which have since reached adoption in over 50 countries.

What is CuraLin?

CuraLin is CuraLife's 100% natural glucose support supplement designed for individuals looking to maintain healthy blood sugar levels, combining ancient Ayurveda practices with modern science.

Which company did CuraLife acquire?

CuraLife acquired GlucoMe in January 2021.